Hologic to Discontinue Fluoroscan InSight FD: Impact on Skeletal Health Division.

Hologic's HOLX Skeletal Health division reported a 62.1% sales jump in Q3 FY25, driven by accelerated production of Horizon DXA systems. The company plans to discontinue the Fluoroscan Insight FD mini C-arm, effective Sept. 30, 2025, which is expected to generate $18 million in product and service revenues in FY25. Hologic has tightened its FY25 revenue range to $4.081-$4.091 billion, supported by a strong Q3 performance and reduced tariff headwinds.

Hologic's HOLX Skeletal Health division reported a significant 62.1% sales jump in the third quarter of fiscal 2025, driven by an accelerated production ramp-up of Horizon DXA systems. The company's strong performance in the quarter helped tighten its fiscal 2025 revenue range to $4.081-$4.091 billion, supported by reduced tariff headwinds HOLX to Discontinue Fluoroscan InSight FD Soon: Will the Stock Suffer?^[1].

The company also announced the end-of-sale and end-of-life for the Fluoroscan Insight FD mini C-arm, effective September 30, 2025. Launched in 2018, the product was designed to assist in performing minimally invasive orthopedic surgical procedures. The discontinuation was a strategic decision based on its low gross margin, limited growth potential, and fit within the company’s overall portfolio. Hologic expects Fluoroscan to generate about $18 million in product and service revenues in fiscal 2025 before it stops selling the product next year HOLX to Discontinue Fluoroscan InSight FD Soon: Will the Stock Suffer?^[1].

The discontinuation of Fluoroscan is not expected to have a significant impact on growth in 2025. However, in 2026, Skeletal revenues will be less than in recent quarters, reflecting the fulfillment of pent-up demand and the phase-out of the Fluoroscan product. The Diagnostics business is expected to continue benefiting from the strength in underlying growth drivers, including the BV, CV/TV molecular diagnostic assay. Breast Health is rebounding and may deliver modest top-line growth in the fourth quarter. Surgical revenues are likely to be the strongest in the final quarter, thanks to an easier year-over-year comparison and better commercial execution. Management also anticipates outsized fourth-quarter growth in Skeletal Health HOLX to Discontinue Fluoroscan InSight FD Soon: Will the Stock Suffer?^[1].